State Medicaid agencies can improve D-SNP financial transparency and reward those D-SNPs that provide the best value to ...

We recently published a list of 10 Tech Stocks with High Upside Potential. In this article, we are going to take a look at ...

Synopsys SNPS shares plunged 20.8% over the past year, underperforming the Zacks Computer - Software industry, Zacks Computer ...

Dual eligibles — that is, people eligible for both Medicare and Medicaid — have a wealth of Medicare options. These ...

Synopsys (NASDAQ:SNPS – Free Report) had its price target decreased by Piper Sandler from $655.00 to $653.00 in a report released on Thursday,Benzinga reports. Piper Sandler currently has an ...

Synopsys Inc (NASDAQ:SNPS) shares are trading higher premarket reported first-quarter financial results after the market ...

In a report released today, Blair Abernethy from Rosenblatt Securities maintained a Buy rating on Synopsys (SNPS – Research Report), with a ...

This post was written by Luke Carberry Mogan. SNPS' first-quarter performance is likely to have benefited from the rising adoption of EDA, IP solutions and Synopsys.ai platform. Get a deeper ...

For the quarter ended January 2025, Synopsys (SNPS) reported revenue of $1.46 billion, down 11.8% over the same period last year. EPS came in at $3.03, compared to $3.56 in the year-ago quarter.

A comprehensive national study examining dementia patient outcomes for Medicare Advantage beneficiaries with Alzheimer's disease and related dementias (ADRD) uncovered key insights into healthcare ...

Loop Capital Markets analyst Gary Mobley reiterated a Buy rating on Synopsys (SNPS – Research Report) today and set a price target of $650.00.